NCT07543120
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 8 words
- Trial sites expanded: 25 → 46 locations
- Primary completion date: May 31, 2031 to May 7, 2031
- Study completion date: Nov 30, 2031 to Nov 7, 2031
- Minor Trial sites expanded: 13 → 25 locationsv4
- Minor Trial sites expanded: 7 → 13 locationsv3
- Notable Recruitment opened
- Trial sites expanded: 0 → 7 locations
- Start date changed from estimate of May 1, 2026 to May 7, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of participants with AEs
Timeframe: Up to 66 months
Secondary (2)
Change in SBP and DBP assessed by ambulatory blood pressure monitoring
Change in SBP and DBP assessed by office blood pressure measurement
Arms and interventions
QCZ484Experimental
QCZ484 administered subcutaneously (SC) Q6M
Drugs: QCZ484
Sites
46 sites in 3 countries
United States 38, Japan 5, Singapore 3